GHO Capital, a private equity firm, agreed to acquire Velocity Clinical Research, a pharmaceutical and vaccine research company, from NaviMed Capital, a private equity firm, for $501m. "Today's announcement signals the future for the clinical trials industry. NaviMed has been a great partner for us, working with us on the direction for the company while giving our senior management team the freedom to execute on strategic decisions. Our experienced team knows how to run sites and we feel that GHO is the right partner to back Velocity, as we move into our next phase of growth thanks to their experience in pharmaceutical services," G. Paul Evans, Velocity President and CEO.